Grindeks to take part in development of Mildronate analogue
This article was originally published in Scrip
Executive Summary
Grindeks has signed an agreement for the development of a structural analogue of its leading product, the cardiovascular Mildronate (meldonium), with the Latvian institute of organic synthesis (OSI) where the original product was discovered. The parties want to find other partners for the project.